via Georgia State University
An influenza vaccine that is made of nanoparticles and administered through the nose enhances the body’s immune response to influenza virus infection and offers broad protection against different viral strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
Recurring seasonal flu epidemics and potential pandemics are among the most severe threats to public health. Current seasonal influenza vaccines induce strain-specific immunity and are less effective against mismatched strains. Broadly protective influenza vaccines are urgently needed.
Intranasal vaccines are a promising strategy for combatting infectious respiratory diseases, such as influenza. They are more effective than vaccines injected into a muscle because they can induce mucosal immune responses in respiratory tracts, preventing infection at the portal of virus entry. They can also stimulate systemic immune responses throughout the body.
Scientists can overcome vaccine safety concerns and the long production phase of virus-based influenza vaccines by constructing intranasal vaccines with recombinant proteins or peptides. However, these vaccines are poor at producing immune responses, so it’s necessary to have potent mucosal adjuvants, substances that enhance the body’s immune response to antigens (the molecular structures on pathogens). The absence of appropriate mucosal adjuvants currently hinders the development of such a vaccine.
In this study, the researchers developed an intranasal influenza vaccine using recombinant hemagglutinin (HA), a protein found on the surface of influenza viruses, as the antigen component of the vaccine. HA is integral to the ability of influenza virus to cause infection.
They also created a two-dimensional nanomaterial (polyethyleneimine-functionalized graphene oxide nanoparticles) and found that it displayed potent adjuvant (immunoenhancing) effects on influenza vaccines delivered intranasally. The findings are published in the journal Proceedings of the National Academy of Sciences.
“Conventional flu vaccines predominantly induce antibody responses,” said Dr. Baozhong Wang, senior author of the study, principal investigator of the National Institutes of Health grant supporting the study and a professor in the Institute for Biomedical Sciences. “However, recent research demonstrates that lung resident memory T cell responses are indispensable for optimal cross-protection against pulmonary influenza infection. The development of lung resident T cell responses requires vaccination by a respiratory route or influenza virus infection. Our research opens a new path for the development of needle-free and logistically simplified intranasal flu vaccines for cross-protection.”
“In our study, we reported for the first time that two-dimensional graphene oxide nanomaterials had a potent adjuvant effect in boosting the immune responses of intranasal hemagglutinin (HA) vaccines,” said Dr. Chunhong Dong, lead author of the study and a postdoctoral research Fellow in Dr. Baozhong Wang’s lab in the Institute for Biomedical Sciences.
“This study gives new insights into developing high performance intranasal vaccine systems with two-dimensional sheet-like nanoparticles,” Dong said. “The graphene oxide nanoparticles have extraordinary attributes for drug delivery or vaccine development, such as the ultra-large surface area for high-density antigen loading, and the vaccine showed superior immunoenhancing properties in vitro and in vivo. The nanoplatform could be easily adapted for constructing mucosal vaccines for different respiratory pathogens.”
The study, conducted in mice and cell culture, found the nanoparticles significantly enhanced immune responses at mucosal surfaces and throughout the body in mice. The robust immune responses conferred immune protection against influenza virus challenges by homologous (same) virus strains and heterologous (different) virus strains.
The results are also promising because needle-free, intranasal influenza vaccines possess superior logistical advantages over traditional injectable vaccines, such as easy administration with high acceptance for recipients and the avoidance of biohazardous waste.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Intranasal nanoparticle influenza vaccine
- Chinese Scientists Propose a New Live-Virus Flu Vaccine
Using attenuated, live viruses as vaccines is a promising strategy to reduce the impact of viral infectious diseases, such as influenza. Traditional live-attenuated virus vaccines have, however, often ...
- Influenza Vaccine Market: Global Analysis, Growth, Trend, Share, Size, Opportunity and Forecast Till 2026
The Global Influenza Vaccine Market was estimated to grow at a CAGR of 5.9% during the forecast period 2019-2026. As per the detailed market study, the global influenza vaccines industry is ...
- Nasal spray highly effective against HIV and SARS-CoV-2 in animal models
Study: Intranasal vaccination with lipid-conjugated immunogens ... have reported that many pathogens such as rotavirus, cholera, influenza, HIV, and SARS-CoV-2 require both systemic and mucosal ...
- Nasal vaccines: What's the latest research on nasal vaccines for Covid?
But that same kind of effort has not been given to developing the next generation of vaccines, which experts believe will provide even greater protection. Nasal vaccines, in particular, may hold a lot ...
- Nasal vaccines may stop Covid infections. Will we get them soon?
Her team is looking at two approaches: a protein-based nasal spray and an mRNA vaccine delivered into the nose using nanoparticles ... in the U.S.: FluMist, an influenza vaccine.
Go deeper with Google Headlines on:
Intranasal nanoparticle influenza vaccine
Go deeper with Bing News on:
Intranasal nanoparticle vaccines
- Dr. Loh: What now, vaccine makers?
In this third summer of COVID, when pandemic fatigue has overwhelmed most of us, we still yearn for that elusive light at the end of this seemingly interminable tunnel.
- New needle-free nasal vaccine shows promise for COVID-19
T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mBio, an open access journal of the American Society for Microbiology.
- Yale vaccine against Omicron shows flexibility of mRNA technology
The mRNA, borne by immune-alerting fatty nanoparticles ... idea the panel proposed appeared to be the development of a nasal spray vaccine to enhance the barrier function of the immune system.
- New class of nanoparticle-based vaccines could help immunize against cancer
A vaccination as tumor therapy—with a vaccine individually created from a patient's tissue sample that "attaches" the body's own immune system to cancer cells. The basis for this long-term vision has ...
- Nasal COVID-19 vaccines may be better at preventing infections, experts say
is also involved in research on nasal vaccines. Her team is investigating both a protein-based spray and an mRNA vaccine, which is delivered into the nose using nanoparticles. Both candidates ...